|
Validation of a genomic risk classifier to predict prostate cancer-specific mortality (PCSM) in high-risk patients. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - GenomeDx |
Consulting or Advisory Role - GenomeDx |
Research Funding - Merck; Metamark Genetics; Novartis |
Travel, Accommodations, Expenses - Sarah Cannon Research Institute |
|
|
Consulting or Advisory Role - GenomeDx; Myriad Genetics |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Travel, Accommodations, Expenses - GenomeDx |
|
|
|
|
|
|
|
Stock and Other Ownership Interests - GenomeDx |
Patents, Royalties, Other Intellectual Property - CANCER DIAGNOSTICS USING BIOMARKERS 20140066323 |
Travel, Accommodations, Expenses - GenomeDx |
|
|
Consulting or Advisory Role - Champions Oncology; GenomeDx; Roche; SonaCare Medical |
Research Funding - Myriad Genetics |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - GenomeDx |